股本结构
单位:万股
公告日期 | 2024-03-28 | 2024-03-28 | 2023-11-09 | 2023-11-09 | 2023-08-30 | 2023-08-30 |
---|---|---|---|---|---|---|
证券总股本 | 10058.19 | 9997.39 | 9856.23 | 9829.23 | 9829.23 | 8829.23 |
普通股本 | 10058.19 | 9997.39 | 9856.23 | 9829.23 | 9829.23 | 8829.23 |
优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
变动日期 | 2024-03-27 | 2023-12-31 | 2023-11-08 | 2023-09-30 | 2023-09-01 | 2023-08-28 |
注释:中概股证券总股本=普通股股本/
存托凭证比例
历史变动
公告日期 | 变动后普通股本(万股) | 变动后优先股(万股) | 变动原因 | 变动日期 |
---|---|---|---|---|
2024-03-28 | 10058.19 | 未披露 | 定期报告 | 2024-03-27 |
2024-03-28 | 9997.39 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of common stock from the exercise of warrants
Issuance of common stock, net of issuance costs
|
2023-12-31 |
2023-11-09 | 9856.23 | 未披露 | 定期报告 | 2023-11-08 |
2023-11-09 | 9829.23 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock and warrants, net of issuance costs
|
2023-09-30 |
2023-08-30 | 9829.23 | 未披露 |
更多>>
Common stock offered 10,000,000 shares by the company
|
2023-09-01 |
2023-08-30 | 8829.23 | 未披露 | 定期报告 | 2023-08-28 |
2023-08-10 | 8778.52 | 未披露 | 定期报告 | 2023-08-09 |
2023-08-10 | 8663.36 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock, net of issuance costs
|
2023-06-30 |
2023-05-11 | 8628.48 | 未披露 | 定期报告 | 2023-05-10 |
2023-04-27 | 8625.25 | 未披露 | 定期报告 | 2023-04-25 |
2023-05-11 | 8617.90 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock from the exercise of warrants
|
2023-03-31 |
2023-03-30 | 8617.90 | 未披露 | 定期报告 | 2023-03-29 |
2022-11-10 | 8482.55 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Stock options exercised
|
2022-09-30 |
2022-08-09 | 8482.09 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock, net of issuance costs
Stock options exercised
|
2022-06-30 |
2022-04-29 | 8471.13 | 未披露 | 定期报告 | 2022-04-26 |
2022-04-29 | 8469.52 | 未披露 | 定期报告 | 2022-04-07 |
2022-03-31 | 8394.41 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock, net of issuance costs
Issuance of common stock from the exercise of warrants
Stock options exercised
Issuance of common stock in connection with milestone payment
|
2021-12-31 |
2021-11-10 | 7660.16 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock, net of issuance costs
Issuance of common stock from the exercise of warrants
Issuance of common stock in connection with milestone payment
|
2021-09-30 |
2021-08-12 | 7052.20 | 未披露 | 定期报告 | 2021-08-09 |
2021-08-12 | 5740.95 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock, net of issuance costs
|
2021-06-30 |
2021-05-13 | 4935.01 | 未披露 | 定期报告 | 2021-05-10 |
2021-05-14 | 4864.52 | 未披露 | 定期报告 | 2021-05-04 |
2021-05-13 | 4731.28 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock
Issuance of common stock from the exercise of warrants
|
2021-03-31 |
2021-03-30 | 4731.28 | 未披露 | 定期报告 | 2021-03-29 |
2021-03-30 | 4159.63 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock
Issuance of common stock from the exercise of warrants
Issuance cost on equity line paid in common stock
Stock options exercised
|
2020-12-31 |
2020-12-22 | 4106.41 | 未披露 | 定期报告 | 2020-12-18 |
2020-11-12 | 3799.00 | 未披露 | 定期报告 | 2020-11-11 |
2020-11-12 | 3360.25 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock
Issuance cost on equity line paid in common stock
Issuance of common stock from the exercise of warrants
|
2020-09-30 |
2020-08-12 | 3155.24 | 未披露 | 定期报告 | 2020-08-11 |
2020-07-15 | 2692.66 | 未披露 | 定期报告 | 2020-07-14 |
2020-08-12 | 2852.40 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock
|
2020-06-30 |
2020-05-15 | 2664.62 | 未披露 | 定期报告 | 2020-05-12 |
2020-05-01 | 2499.12 | 未披露 | 定期报告 | 2020-04-27 |
2020-05-14 | 2470.06 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock
Issuance of common stock from the exercise of warrants
Stock options exercised
|
2020-03-31 |
2020-03-27 | 2469.04 | 未披露 | 定期报告 | 2020-03-26 |
2020-03-27 | 1968.34 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock via public offering, net
Equity issued in consideration of acquisition
|
2019-12-31 |
2019-08-14 | 1668.34 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Issuance of common stock via public offering, net
|
2019-06-30 |
2019-04-30 | 1668.34 | 未披露 | 定期报告 | 2019-04-22 |
2018-05-14 | 1142.22 | 未披露 |
更多>>
from December 31, 2017 to March 31, 2018
Net proceeds from issuance of common stock and warrants
Issuance of common stock via public offering, net
|
2018-03-31 |
2018-03-28 | 1142.22 | 未披露 | 定期报告 | 2018-03-26 |
2018-03-28 | 604.72 | 未披露 |
更多>>
from December 31, 2016 to September 30, 2017
Conversion of convertible notes into common stock
Business combination upon merger
|
2017-09-30 |
2017-08-14 | 604.72 | 未披露 |
更多>>
Reverse Stock Split — on July 20, 2017, the Company effected a 1-for-10 reverse stock split of its outstanding common stock (the “Reverse Stock Split”). The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the Reverse Stock Split for all periods presented. The shares of common stock retained a par value of $0.0001 per share. Accordingly, stockholders’ equity reflects the Reverse Stock Split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.
|
2017-08-10 |
2017-07-20 | 604.72 | 未披露 |
更多>>
Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience Operations, Inc. (formerly Daré Bioscience, Inc.) today announced a one-for-ten reverse stock split of the combined company’s common stock will be effected on Thursday, July 20, 2017. There will be approximately 6,047,200 shares of Daré common stock issued and outstanding after the split.
|
2017-07-20 |
2015-08-06 | 2730.01 | 未披露 | 定期报告 | 2015-06-30 |
2015-05-06 | 2056.80 | 未披露 | 定期报告 | 2015-03-31 |
2014-11-13 | 2012.48 | 未披露 | 定期报告 | 2014-09-30 |
2014-08-12 | 2012.30 | 未披露 | 定期报告 | 2014-06-30 |
From December 31, 2022 to December 31, 2023
Issuance of common stock from the exercise of warrants
Issuance of common stock, net of issuance costs
From June 30, 2023 to September 30, 2023
Issuance of common stock and warrants, net of issuance costs
Common stock offered 10,000,000 shares by the company
From March 31, 2023 to June 30, 2023
Issuance of common stock, net of issuance costs
From December 31, 2022 to March 31, 2023
Issuance of common stock from the exercise of warrants
From June 30, 2022 to September 30, 2022
Stock options exercised
From March 31, 2022 to June 30, 2022
Issuance of common stock, net of issuance costs
Stock options exercised
From December 31, 2020 to December 31, 2021
Issuance of common stock, net of issuance costs
Issuance of common stock from the exercise of warrants
Stock options exercised
Issuance of common stock in connection with milestone payment
From June 30, 2021 to September 30, 2021
Issuance of common stock, net of issuance costs
Issuance of common stock from the exercise of warrants
Issuance of common stock in connection with milestone payment
From March 31, 2021 to June 30, 2021
Issuance of common stock, net of issuance costs
From December 31, 2020 to March 31, 2021
Issuance of common stock
Issuance of common stock from the exercise of warrants
From December 31, 2019 to December 31, 2020
Issuance of common stock
Issuance of common stock from the exercise of warrants
Issuance cost on equity line paid in common stock
Stock options exercised
From June 30, 2020 to September 30, 2020
Issuance of common stock
Issuance cost on equity line paid in common stock
Issuance of common stock from the exercise of warrants
From March 31, 2020 to June 30, 2020
Issuance of common stock
From December 31, 2019 to March 31, 2020
Issuance of common stock
Issuance of common stock from the exercise of warrants
Stock options exercised
from December 31, 2018 to December 31, 2019
Issuance of common stock via public offering, net
Equity issued in consideration of acquisition
from March 31, 2019 to June 30, 2019
Issuance of common stock via public offering, net
from December 31, 2017 to March 31, 2018
Net proceeds from issuance of common stock and warrants
Issuance of common stock via public offering, net
from December 31, 2016 to September 30, 2017
Conversion of convertible notes into common stock
Business combination upon merger
Reverse Stock Split — on July 20, 2017, the Company effected a 1-for-10 reverse stock split of its outstanding common stock (the “Reverse Stock Split”). The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the Reverse Stock Split for all periods presented. The shares of common stock retained a par value of $0.0001 per share. Accordingly, stockholders’ equity reflects the Reverse Stock Split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.
Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience Operations, Inc. (formerly Daré Bioscience, Inc.) today announced a one-for-ten reverse stock split of the combined company’s common stock will be effected on Thursday, July 20, 2017. There will be approximately 6,047,200 shares of Daré common stock issued and outstanding after the split.